New Zenith publication! Artificial Intelligence guided dose optimization of ZEN-3694 and enzalutamide combo aids treatment of mCRPC. It was just one patient in this study, but this may have been one of the rock star patients in the ZEN-3694/enzalutamide combo trial. Dr. Dean Ho, Director of the Singapore Institute for Neurotechnology (SINAPSE) at National University of Singapore (NUS) led the study. This study was conducted at UCLA with publication lead author and ZEN-3694 clinical investigator Allan Pantuck.
Modulating BET Bromodomain Inhibitor ZEN‐3694 and Enzalutamide Combination Dosing in a Metastatic Prostate Cancer Patient Using CURATE.AI, an Artificial Intelligence Platform
Abstract:
Combination chemotherapy is a cornerstone of cancer treatment. Optimizing its effectiveness requires dose‐ and time‐dependent regulation of drug synergy. In this report, CURATE.AI, an artificial intelligence platform, is used to prospectively guide the dosing of a bromodomain inhibitor (ZEN‐3694) and enzalutamide administered in combination to a patient with metastatic castration‐resistant prostate cancer to reduce serum prostate‐specific antigen (PSA) levels. CURATE.AI successfully identifies substantial ZEN‐3694 and enzalutamide dose adjustments, increasing both treatment efficacy and tolerance. CURATE.AI analysis also confirms that the patient's durable response is mediated by ZEN‐3694 inclusion in the regimen. Due to CURATE.AI‐enhanced efficacy and safety, the patient was able to continue with the combination regimen, resulting in a durable response and no disease progression based on CURATE.AI‐sustained control over PSA levels and reduced lesion size.
Related article from National University of Singapore (NUS) "NUS researchers use AI to successfully treat metastatic cancer patient: Groundbreaking CURATE.AI platform halts progression of advanced cancer in clinical study by continuously optimising novel drug combination."
https://news.nus.edu.sg/press-releases/nus-researchers-use-ai-successfully-treat-metastatic-cancer-patient
Great news in advance of the upcoming AGM!
BearDownAZ
